definiens: shall mean the use of [COMPANY] Po loxamer Intellectual Property in polynucleotide - bas ed therapeutics and prophylactics ( including DNA, RNA, viral, and all other biologically active natural a nd synthetic polynucleotides such as antisense ( includ ing antisense polynucleotides containing phosphothi oester moieties ) and CpG materials ) alone or in combinatio n with a protein or peptide antigen as part of a pr ime / boost regime, for all human and animal health application s, except for the following : a ) those fields of use currently licensed to Merck, as described in the Merck License, b ) DNA vaccines and / or therapeutics based on PSMA ( as defined in Section 1.17 hereof ), c ) sale of a non - regulated product for use as a non -clinical research reagent to increase transfection in vitro or in laboratory animals . For the avoidance of any doubt, [COMPANY] shall be free to license the [COMPANY] Poloxamer Intellectual Property in therapeutics and prophylac tics ( including prime - boost regimes ) that do not in clude polynucleotides